tPA Administration in Patients on Eliquis (Apixaban)

Current Guideline Recommendations

The Canadian Stroke Best Practice Recommendations state that tPA should not routinely be administered to patients on direct oral anticoagulants (DOACs) presenting with acute ischemic stroke until there is a commercially available and validated assessment tool for DOAC levels and reliable clinical interpretation of these levels 1
The American College of Cardiology and other guideline societies implicitly support this recommendation by emphasizing the importance of careful patient selection for tPA therapy, especially in the context of anticoagulation 1

The combination of systemic anticoagulation with tPA carries a high risk of bleeding, particularly symptomatic intracranial hemorrhage 2
The baseline symptomatic intracranial hemorrhage rate with tPA alone is approximately 4-6%, and this risk is substantially elevated in anticoagulated patients 3, 4

Obtain non-contrast head CT immediately to exclude intracranial hemorrhage, and document time of symptom onset and last apixaban dose 1, 2
Obtain CT angiogram to identify large vessel occlusion, and if present, proceed directly to mechanical thrombectomy consultation 1, 2
If patient is on apixaban, do NOT administer tPA as routine practice 1

Time is brain—obtain CT and CT angiogram emergently to determine if mechanical thrombectomy is an option 1
Standard coagulation tests (PT/INR, aPTT) do not reliably measure apixaban levels and should not be used to guide tPA decisions 1
While tPA is contraindicated, mechanical thrombectomy remains a viable option and should be actively pursued 1, 2

Even with extended time from last dose, current guidelines recommend against routine tPA use without validated anticoagulant level testing 1
Aspirin therapy (160-325 mg) should be initiated after excluding intracranial hemorrhage, as this is recommended for acute ischemic stroke patients not receiving tPA 1, 3, 5